Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells $2,015,818.00 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 95,900 shares of the business’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $21.02, for a total value of $2,015,818.00. Following the completion of the transaction, the director directly owned 1,086,063 shares of the company’s stock, valued at approximately $22,829,044.26. The trade was a 8.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Performance

Shares of NASDAQ DYN opened at $20.94 on Monday. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. The stock has a market capitalization of $3.46 billion, a P/E ratio of -6.50 and a beta of 1.09. Dyne Therapeutics, Inc. has a 1-year low of $8.06 and a 1-year high of $25.00. The business has a fifty day moving average price of $18.45 and a 200 day moving average price of $18.08.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same period in the prior year, the company posted ($1.05) EPS. Equities research analysts expect that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

DYN has been the topic of a number of recent analyst reports. Morgan Stanley lowered their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 20th. Chardan Capital reissued a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 9th. Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Finally, HC Wainwright cut their price target on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.17.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DYN. JPMorgan Chase & Co. grew its stake in shares of Dyne Therapeutics by 9.0% during the third quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company’s stock worth $42,570,000 after acquiring an additional 278,466 shares during the last quarter. Aberdeen Group plc increased its holdings in shares of Dyne Therapeutics by 99.0% during the fourth quarter. Aberdeen Group plc now owns 1,108,145 shares of the company’s stock valued at $21,675,000 after acquiring an additional 551,412 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Dyne Therapeutics by 27.6% in the 3rd quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock valued at $123,469,000 after purchasing an additional 2,109,257 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Dyne Therapeutics in the 4th quarter valued at approximately $5,191,000. Finally, Fisher Asset Management LLC acquired a new stake in Dyne Therapeutics in the 4th quarter worth approximately $4,891,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.